These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27634505)

  • 1. Cystic fibrosis foundation opens drug discovery lab.
    Trivedi BP
    Science; 2016 Sep; 353(6305):1194-5. PubMed ID: 27634505
    [No Abstract]   [Full Text] [Related]  

  • 2. Reshma Kewalramani.
    Mullard A
    Nat Rev Drug Discov; 2019 Nov; 18(12):896-897. PubMed ID: 31780855
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug bests cystic-fibrosis mutation.
    Ledford H
    Nature; 2012 Feb; 482(7384):145. PubMed ID: 22318583
    [No Abstract]   [Full Text] [Related]  

  • 4. Excitement mounts for first disease-modifying cystic fibrosis drugs.
    Opar A
    Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393
    [No Abstract]   [Full Text] [Related]  

  • 5. Personalized medicine. New cystic fibrosis drug offers hope, at a price.
    Kaiser J
    Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790
    [No Abstract]   [Full Text] [Related]  

  • 6. Orphan cystic fibrosis drugs find sister diseases.
    Dolgin E
    Nat Med; 2011 Apr; 17(4):397. PubMed ID: 21475214
    [No Abstract]   [Full Text] [Related]  

  • 7. PharmGKB summary: very important pharmacogene information for CFTR.
    McDonagh EM; Clancy JP; Altman RB; Klein TE
    Pharmacogenet Genomics; 2015 Mar; 25(3):149-56. PubMed ID: 25514096
    [No Abstract]   [Full Text] [Related]  

  • 8. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
    Jones AM; Barry PJ
    Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
    [No Abstract]   [Full Text] [Related]  

  • 9. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
    Birault V; Solari R; Hanrahan J; Thomas DY
    Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological approaches to cystic fibrosis.
    Bandiera T; Galietta LJV
    Eur J Med Chem; 2021 Apr; 216():113240. PubMed ID: 33691259
    [No Abstract]   [Full Text] [Related]  

  • 11. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
    van Koningsbruggen-Rietschel S; Naehrlich L
    Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
    [No Abstract]   [Full Text] [Related]  

  • 12. Biotechnology. Disease group invests in do-it-yourself drugs.
    Marshall E
    Science; 2000 Jun; 288(5472):1715-7. PubMed ID: 10877679
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel pharmacologic therapies for cystic fibrosis.
    Zeitlin PL
    J Clin Invest; 1999 Feb; 103(4):447-52. PubMed ID: 10021451
    [No Abstract]   [Full Text] [Related]  

  • 14. Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis.
    Gelman MS; Kopito RR
    J Clin Invest; 2002 Dec; 110(11):1591-7. PubMed ID: 12464661
    [No Abstract]   [Full Text] [Related]  

  • 15. Pluripotent Stem Cell Platforms for Drug Discovery.
    Chen KG; Mallon BS; Park K; Robey PG; McKay RDG; Gottesman MM; Zheng W
    Trends Mol Med; 2018 Sep; 24(9):805-820. PubMed ID: 30006147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CFTR mutations and cystic fibrosis.
    Prescrire Int; 2013 Oct; 22(142):232. PubMed ID: 24298580
    [No Abstract]   [Full Text] [Related]  

  • 17. New pharmaceutical approaches to the treatment of cystic fibrosis.
    Delaney SJ; Wainwright BJ
    Nat Med; 1996 Apr; 2(4):392-3. PubMed ID: 8597941
    [No Abstract]   [Full Text] [Related]  

  • 18. [Modifier genes and cystic fibrosis].
    Corvol H; Flamant C; Vallet C; Clement A; Brouard J
    Arch Pediatr; 2006 Jan; 13(1):57-63. PubMed ID: 16274977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting nonsense-mediated cystic fibrosis: is it premature to stop now?
    O'Sullivan BP
    Lancet Respir Med; 2014 Jul; 2(7):509-11. PubMed ID: 24836206
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting the basic defect in cystic fibrosis.
    Welsh MJ
    N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.